Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.42 |
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14099337 | 0.86 | KIF11 (0.49) | PRSS1PRSS2PRSS3F10PLAU | |
| Hydrochloric Acid SCHEMBL5125320 | 0.85 | KIF11 (0.47) | PRSS1PRSS2PRSS3F10PLAU | |
| SCHEMBL16527165 | 0.81 | PTPN7 (0.47) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL273364 | 0.81 | VNN1 (0.54) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL30641942 | 0.81 | VNN1 (0.54) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL19479019 | 0.81 | MAPT (0.46) | PRSS1PRSS2PRSS3F10PLAU | |
| SCHEMBL4399666 | 0.80 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| Hydrochloric Acid SCHEMBL28325793 | 0.79 | MAPT (0.45) | PRSS1PRSS2PRSS3F10PLAU | |
| SCHEMBL6503335 | 0.79 | PRSS1 (0.41) | PRSS1PRSS2PRSS3F10PLAU | |
| Hydrochloric Acid SCHEMBL4372865 | 0.79 | VNN1 (0.53) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699041-B | Imidazole derivative having JNK inhibitory activity and use thereof | 三进制药株式会社 | 2021-03-26 | — | — | CN | disclosed |
| EP-3409668-B1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2020-10-21 | — | — | EP | disclosed |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-05-28 | — | — | US | disclosed |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-05-28 | — | — | US | disclosed |
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-31 | — | — | US | disclosed |
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-3409668-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-05 | — | — | EP | disclosed |
| CN-108699041-A | Novel imidazole derivatives and application thereof with JNK inhibitory activity | 三进制药株式会社 | 2018-10-23 | — | — | CN | disclosed |
| WO-2017131425-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | 한양대학교 에리카산학협력단 | 2017-08-03 | — | — | WO | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | MAPKAPK2, MAPKAPK3, MAP3K7 | PRSS1 1449/4885PRSS2 1899/4885PRSS3 2210/4885 |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | MAPKAPK2, MAPKAPK3, MAP3K7 | PRSS1 1539/4885PRSS2 1922/4885PRSS3 2299/4885 |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | PRSS1 1912/4885PRSS2 3185/4885PRSS3 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.